ASCO 2017 – CLL

A quantitative analysis revealed substantially different activity profiles for ibrutinib and chlorambucil in the circulating cells during the first year of treatment in patients with chronic lymphocytic leukemia (CLL). Read More ›

This 2-cohort, phase 2 study will investigate a CD19 antibody, MOR208, combined with idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase inhibitor. Read More ›

This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL). Read More ›

CALGB 10404, a randomized phase 2 study, compares different fludarabine chemoimmunotherapy regimens in patients with non-del(11q) chronic lymphocytic leukemia (CLL). Read More ›

GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib. Read More ›

This retrospective cohort study examines the use and efficacy of ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter transformation. Read More ›

Researchers are evaluating ibrutinib with prednisone as a potential treatment option for patients with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD). Read More ›

A phase 1 study evaluates the efficacy and toxicity of the combination of ibrutinib and buparlisib in relapsed/refractory non-Hodgkin lymphoma. Read More ›

The phase 2 KI Intolerance Study was undertaken to assess the safety and efficacy of TGR-1202, a next-generation, highly specific PI3Kδ inhibitor, in patients with chronic lymphocytic leukemia (CLL). Read More ›

A phase 2 study was conducted to examine the efficacy and safety of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for previously untreated patients with mutated IGHV chronic lymphocytic leukemia (CLL). Read More ›

Page 1 of 2